Magnesium Oxide Hydrate Bioavailability via Parameter Changes

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current magnesium supplements face challenges with low bioavailability and absorption rates, leading to inadequate cellular uptake and potential side effects like diarrhea and nausea, due to the agglomeration of magnesium oxide particles and inefficient release of ionized magnesium.

Innovation Solution

A hydrate form of magnesium oxide (MgO·(H2O)n, extracted from the Dead Sea, is used to enhance bioavailability by improving dissolution and generating free magnesium ions under physiological conditions, overcoming agglomeration issues and increasing intracellular absorption.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional magnesium oxide supplements are used, then magnesium supplementation is provided, but bioavailability and absorption rates are low due to particle agglomeration

Engineering Contradiction:
ImprovebioavailabilityVSAvoidparticle agglomeration
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the physical-chemical parameters of magnesium oxide by converting it to a hydrate form (MgO·xH2O) with specific surface area characteristics. This parameter change prevents particle agglomeration and enhances dissolution in physiological fluids, thereby improving bioavailability and absorption rates while maintaining the supplement function.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If conventional magnesium supplements are used, then magnesium is supplied, but cellular uptake is inadequate leading to side effects like diarrhea and nausea

Engineering Contradiction:
Improvecellular uptakeVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical form of magnesium from conventional oxide to a specific hydrate form with controlled surface area (5-50 m²/g). This parameter change enables controlled dissolution and ionization in physiological fluids, improving cellular uptake efficiency and reducing gastrointestinal side effects by preventing excessive rapid release.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The hydrate form acts as an intermediary between conventional magnesium oxide and cellular absorption. The specific surface area characteristics of the hydrate form facilitate controlled interaction with physiological fluids, enabling gradual ionization and absorption that prevents the harmful effects of rapid magnesium release while ensuring adequate cellular uptake.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The magnesium oxide hydrate form significantly enhances cellular uptake of magnesium, reducing side effects and improving therapeutic efficacy by maintaining elevated intracellular magnesium levels, thus addressing the limitations of existing magnesium supplements.

Implementation Method 1

improving dissolution and generating free magnesium ions under physiological conditions

Methodology Applied
Scientific EffectDissolution: Solvation

Implementation Method 2

A hydrate form of magnesium oxide (MgO·(H2O)n) is used to enhance bioavailability

Methodology Applied
Scientific EffectHydration: Hydrates

Data Source

PatentEP2805724B1Magnesium oxide hydrate-containing products and uses thereof
Publication Date: 2018.09.19 NAVEH PHARMA 1996
  • EP2805724B1 patent drawingFigure 1
  • EP2805724B1 patent drawingFigure 2~3
  • EP2805724B1 patent drawingFigure 4~5A

AI summary

A composition including a hydrate form of magnesium oxide, denoted as MgO·(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt%), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt%; or Mg(OH)2, at a concentration ranging from 0 to 99 wt%; or Mg(OH)2 at a concentration ranging from 0 to 99 wt%, and MgO, at a concentration ranging from 0 to 99 wt%.